key: cord-0818035-svempphd authors: Banerjee, A.; Chen, S.; Pasea, L.; Lai, A.; Katsoulis, M.; Denaxas, S.; Nafilyan, V.; Williams, B.; Wong, W. K.; Bakhai, A.; Khunti, K.; Pillay, D.; Noursadeghi, M.; Wu, H.; Pareek, N.; Bromage, D.; Mcdonagh, T.; Byrne, J.; Teo, J. T.; Shah, A.; Humberstone, B.; Tang, L. V.; Shah, A. S.; Rubboli, A.; Guo, Y.; Hu, Y.; Sudlow, C. L.; Lip, G. Y.; Hemingway, H. title: Excess deaths in people with cardiovascular diseases during the COVID-19 pandemic. date: 2020-06-11 journal: nan DOI: 10.1101/2020.06.10.20127175 sha: f22d654d94c461ffd15f46bf1d827f6cd0362bdf doc_id: 818035 cord_uid: svempphd Background: Cardiovascular diseases(CVD) increase mortality risk from coronavirus infection(COVID-19), but there are concerns that the pandemic has affected supply and demand of acute cardiovascular care. We estimated excess mortality in specific CVDs, both direct, through infection, and indirect, through changes in healthcare. Methods: We used population-based electronic health records from 3,862,012 individuals in England to estimate pre- and post-COVID-19 mortality risk(direct effect) for people with incident and prevalent CVD. We incorporated: (i)pre-COVID-19 risk by age, sex and comorbidities, (ii)estimated population COVID-19 prevalence, and (iii)estimated relative impact of COVID-19 on mortality(relative risk, RR: 1.5, 2.0 and 3.0). For indirect effects, we analysed weekly mortality and emergency department data for England/Wales and monthly hospital data from England(n=2), China(n=5) and Italy(n=1) for CVD referral, diagnosis and treatment until 1 May 2020. Findings: CVD service activity decreased by 60-100% compared with pre-pandemic levels in eight hospitals across China, Italy and England during the pandemic. In China, activity remained below pre-COVID-19 levels for 2-3 months even after easing lockdown, and is still reduced in Italy and England. Mortality data suggest indirect effects on CVD will be delayed rather than contemporaneous(peak RR 1.4). For total CVD(incident and prevalent), at 10% population COVID-19 rate, we estimated direct impact of 31,205 and 62,410 excess deaths in England at RR 1.5 and 2.0 respectively, and indirect effect of 49932 to 99865 excess deaths. Interpretation: Supply and demand for CVD services have dramatically reduced across countries with potential for substantial, but avoidable, excess mortality during and after the COVID-19 pandemic. Coronavirus disease 2019 has had unplanned consequences for non-COVID-19 health services. We described reductions in urgent cancer referrals and chemotherapy compared to pre-COVID-19 levels 1 . Decreases in presentation and treatment of myocardial infarction(MI) [2] [3] [4] in Italy and the USA suggest effects on care, but services have not been studied across specific CVDs, countries or different phases of the pandemic. Early reports from Wuhan, China, demonstrated high prevalence of and mortality from COVID-19 in individuals with CVD; confirmed across countries, particularly with coronary heart disease(CHD) and heart failure(HF) 5-8 . UK government policy for "physical distancing" in high-risk subgroups for COVID-19, announced on 16 March 2020, included CVD, especially HF 9 . On 22 March 2020, a further 1.5 million people in England(with 'extremely vulnerable' conditions) were recommended at least 12 weeks of 'shielding' 10 , excluding those with CVD, prior to UK lockdown on 23 March 11 . Better understanding of pre-and post-COVID-19 mortality risk across specific CVDs may help decisions and policies regarding physical isolation. Therefore, effects of COVID-19 on individuals and health systems are: (i)direct due to infection, and (ii)indirect due to unprecedented system strain and associated behaviour changes 12 . Those with CVD, carrying the greatest burden of global morbidity and mortality 13 , are likely to be particularly affected. Beyond direct effects, systematic examination of recent and longer-term trends for CVD services may help in planning the timing and nature of exit from lockdown and strategies for any subsequent infection peaks. Moreover, reductions in rates of referral, diagnosis, and treatment, may have fatal long-term consequences, caused by "supply"(e.g. lower healthcare availability) and/or "demand"(e.g. delayed presentation), but have not been investigated. Electronic health records(EHR) have been used in studies across different specific CVDs 14 , and enable novel insights regarding direct and indirect COVID-19-related excess deaths, across incident and prevalent CVD, and the spectrum of care. Objective: We used: (i)national mortality data for England and Wales to investigate trends in non-COVID-19 and CVD excess deaths; (ii)routine data from hospitals in England, Italy and China to assess indirect effects on services for referral, diagnosis and treatment of CVD during the pandemic; and (iii)population-based EHR in England to investigate pre-COVID-19 mortality by underlying risk factors and excess mortality during the COVID-19 pandemic. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.10.20127175 doi: medRxiv preprint To estimate pre-COVID-19 incidence and mortality in individuals with CVD and comorbidities, we used EHR across primary care(Clinical Practice Research Datalink, CPRD-GOLD), hospital care(Hospital Episodes Statistics, HES), and death registry(Office of National Statistics, ONS) with prospective recording and follow-up; linked by CPRD and NHS Digital using unique healthcare identifiers 15 . Over 99% of England's population is registered with general practice(GP). CPRD is representative by socio-demography, ethnicity and overall mortality 16 Weekly/monthly information on CVD care and mortality We obtained: (i)weekly cause-specific mortality data for England and Wales from ONS 19 and cardiac-related attendance data from the Emergency Department(ED) Syndromic Surveillance System for England 20 ; (ii)monthly referral, diagnosis and treatment data for All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Estimating incidence rates and 1-year mortality We estimated incidence rates per 100,000 person-years and pre-COVID- 19 1-year mortality risk for incident and prevalent CVD using Kaplan-Meier analyses stratified by specific CVD and number of (non-CVD) comorbidities(0, 1, 2 and 3+), scaling up from CALIBER Given service changes in CVD observed across countries 2-4 , to capture direct and indirect excess deaths, we modelled in addition to the 10% infected, 40% and 80% affected rates, where 30% and 70% of the population respectively would be un-infected but affected at corresponding RRs. Based on RRs from ONS data(peak RR 1.14 for excess CVD deaths and 1.29 for excess non-COVID-19 deaths; Figure 2 ) and likely longer-term effects on CVD mortality, we estimated direct and indirect excess deaths together by applying RR 1. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.10.20127175 doi: medRxiv preprint In China (both Wuhan and other hospitals) and Italy, activity(referral, diagnosis and treatment) was significantly reduced compared with pre-COVID levels. In Wuhan, there was 83.4% reduction in referral, 92% in diagnosis and 99% in treatment levels of MI by the 1 February, a month after the outbreak started. Corresponding decreases were 92%, 97% and 87% for stroke, 83%, 93% and 98% for HF, and 83%, 95% and 94% for AF. Tianmen and Xiantao demonstrated equivalent decreases across all four disease services. Although decreases were relatively less in Zaoyang and Xiangtang, there were 40-80% reductions across services, except for diagnosis of MI which increased in Zaoyang between January and March. Even after easing and stopping of lockdown, Wuhan reported 50-100% decreases in services for MI, stroke, HF and AF. In other Chinese hospitals, activity had mostly returned to pre-COVID levels by April 2020. Recovery of activity began to occur during the lockdown period and differed across Chinese hospitals, suggesting possible differences in infection rates, patient presentation and behaviour, clinician behaviour and COVID-19-related system strain. In Italy, decreases ranged from 45% for stroke treatment to 94% for HF treatment and 100% for AF diagnosis. In England, there was reduced activity across CVDs during the pandemic. Services in Italy and England had not reached pre-COVID levels even by the easing of lockdown. Across countries, referral rates for all diseases and treatment of MI were particularly affected and declines in activity occurred before the peak of cases or deaths (Figure 1 ). Non-COVID-19 and CVD-related deaths in England and Wales increased in the same chronology as total(including COVID-19) deaths until mid-May 2020(compared with the same week over the last 5 years). The peak observed RR for CVD deaths was in the week ending 24 April(1850 vs 1626 deaths, RR 1.14) and the lowest in the week ending 8 May 2020(1318 vs 1487 deaths, RR 0.89). The same trend was present regardless of whether the RR was calculated compared to the average of previous years, or pre-COVID-19(3 January 2020). Between 6 and 27 March, cardiac ED attendances decreased in England(minimum RR 0.57) and were had not fully recovered on 15 May, which was after easing of lockdown (Figure 2 ). Incidence, prevalence and pre-COVID-19 mortality for CVD All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 11, 2020. and stroke(63,276). Mortality rates were relatively lower for prevalent CVDs (Figure S2) . Across incident and prevalent CVDs, prevalence of 0, 1, 2 and 3+ co-morbidities was 26 Figure S3 ). Comorbidity profiles were similar in those with prevalent CVD (Figure S4) . Multimorbidity was associated with increased 1-year mortality, e.g. in incident AF, 1-year mortality was 31% vs 9% in men and 34% vs 16% in women for ≥ 3 vs 0 conditions. One-year mortality risks were >50% in those with incident cardiac arrest or intracerebral haemorrhage and and at 80% COVID-19 rate, we estimated 8026 vs 3417 excess deaths in multimorbidity All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.10.20127175 doi: medRxiv preprint compared with no comorbidities at corresponding RRs( Figure 4B ). Among those with prevalent CVDs, we estimated higher excess deaths at 1 year than for incident CVDs with similar associations with number of comorbidities( Figure 5B ). There is debate about which conditions should be on "high-risk" and "extremely vulnerable" lists of conditions for physical isolation policies, which should include some CVDs and combinations of comorbidities, based on our risk estimates and COVID-death data todate 6,12 . CVD is known to have high prevalence, incidence and mortality, varying by arterial territory. We now show that AF, CHD, HF, stable angina, and DVT have the highest pre-COVID-19 incidence rates. Prognosis varies by incident versus prevalent disease, specific CVD and number and combination of comorbidities, highlighting need for individualised risk All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.10.20127175 doi: medRxiv preprint prediction across CVD. On a different note, our findings also bring into question the rationale for looking at composite endpoints such as "MACE"(major adverse cardiovascular events) in trials and other studies due to highly variable risk across specific CVD 28 . In individuals with CVD at 10% population infection rate, there would be 50,937 excess deaths at RR 1.5, with higher rates at higher infection rates. An earlier lockdown, as in New Our findings may have implications for which aspects of health services(acute vs chronic, treatment vs prevention, across specific CVDs) require attention at different pandemic phases. Demand for NCD care is documented in humanitarian emergencies 29 , but NCD surveillance is absent in pandemic preparedness, planning and responses, particularly in low-middle income countries 13 , where our findings will be magnified. The learning health system concept 30 , where near real-time data inform science, evidence and care, has not been used optimally during the COVID-19 pandemic, but our CVD referral, diagnosis and treatment data show that data need not be complex. Our study uses large-scale, nationally representative EHR with validated definitions across a comprehensive list of specific CVDs and comorbidities. We present real-time service data from three countries. There are several limitations. In the UK, our study population was 5% of the overall population. We do not have country-level data outside the UK. Our analyses of risk and excess deaths use retrospective EHR data. Our model assumes static infection rate and RR and do not include changes over time. We used service data from limited hospitals and only UK(ONS) administrative data was available. We do not report primary care or community level data regarding CVD services. We modelled using limited comorbidities and simple multimorbidity counts, and did not study impact of ethnicity. We assumed the same effect across all specific CVDs. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.10.20127175 doi: medRxiv preprint There is a substantial avoidable burden of excess mortality in people with CVD during the COVID-19 pandemic. Excess CVD deaths can be reduced in more integrated approaches, focused on reducing COVID-19 infection rates, as well as managing CVD and comorbidities. Research question: AB, GYHL, HH (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 11, 2020. . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 11, 2020. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.10.20127175 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 11, 2020. . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Figure 2 . Weekly national data for excess total, non-COVID and cardiovascular deaths in England and Wales, and emergency department cardiac attendances for England: relative risks. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint A. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.10.20127175 doi: medRxiv preprint Figure 4 : Estimated number excess deaths at 1 year due to COVID-19 pandemic by CVD type for: (A) incident cases; and (B) number of comorbidities for incident cases. A. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.10.20127175 doi: medRxiv preprint Estimating excess mortality in people with cancer and multimorbidity in the COVID-19 emergency Società Italiana di Cardiologia and the CCU Academy investigators group. Reduction of Hospitalizations for Myocardial Infarction in Italy in the COVID-19 Era PM address to the nation on coronavirus Estimating excess 1-year mortality from COVID-19 according to underlying conditions and age in England: a rapid analysis using NHS health records in 3.8 million adults Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people UK phenomics platform for developing and validating electronic health record phenotypes: CALIBER Ethnicity and the first diagnosis of a wide range of cardiovascular diseases: associations in a linked electronic health record cohort of 1 million patients Prevention Treatment of VTE Associated with COVID-19 Infection Consensus Statement Group Global Alliance for Chronic Disease researchers' statement on multimorbidity Office of National Statistics. Deaths involving COVID-19, England and Wales: deaths occurring in Deaths by single year of age tables Medical Treatment Expert Group for COVID-19. Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China The OpenSAFELY Collaborative OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients European Society of Cardiology. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic Trends in excess cancer and cardiovascular deaths in Scotland during the COVID-19 pandemic Cardiovascular outcome trials of glucose-lowering medications: an update Non-communicable diseases in emergencies: a call to action Can the NHS be a learning healthcare system in the age of digital technology